TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.

The Q1 2024 Pulse on Progress newsletter highlights all of the recently launched solutions available to the public and our upcoming events. Read on to see how TransCelerate is helping to improve the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapies.

TransCelerate CEO Janice Chang joined Rob Goodwin (Pfizer), Ester Krofah (Milken Institute Health), Joni Rutter (National Center for Advancing Translational Sciences, National Institutes of Health), and Janet Woodcock (former Principal Deputy Commissioner, Food & Drug Administration) for a special panel on "Inspiring Inclusion: The Power of Pivotal Moments" in honor of International Women's Day.

TransCelerate's 2023 Annual Achievements Report is now available. Read on for an in-depth look at our impact within biopharma R&D, our publicly available solutions and resources, and how we are working to converge clinical research with clinical care.

Gilead Sciences, Inc. (Gilead), a leading biopharmaceutical company that has achieved breakthroughs in medicine for more than three decades, has joined TransCelerate as its newest member.

TransCelerate and ACRO co-created an infographic highlighting key changes to the risk management elements within Good Clinical Practice. It aims to allow the R&D industry to easily identify the impact to their process and how to react for efficient ICH E6 (R3) implementation.

Merz Aesthetics, a leader in aesthetics with an award-winning line of injectables, devices, and skin care products, has joined TransCelerate BioPharma as an Associate Member.

The TransCelerate Site Qualification and Training (SQT) Initiative has developed a Mutual Recognition (MR) Program for ICH E6 Good Clinical Practice (GCP) Training, targeted to investigator site personnel. Our GCP Mutual Recognition program was created to reduce redundant training and hours spent by investigators who need to complete the same training if they work with multiple sponsors.

TransCelerate Member Companies have translated select solutions for potential use within the broader global community. Current translations include solutions concerning Common Protocol Template, Site Qualification & Training, Quality Management Systems and Patient Experience.